Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. The webcast replay will be available approximately two hours after the event and will be archived for 90 days.
About Corbus
Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
INVESTOR CONTACT:
Brian Walsh, VP, Corporate Development
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +1 (781) 264 8944
| Last Trade: | US$12.44 |
| Daily Change: | -0.16 -1.27 |
| Daily Volume: | 118,483 |
| Market Cap: | US$151.520M |
January 08, 2025 December 09, 2024 December 03, 2024 November 21, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
